-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On September 23, the CDE official website showed that the clinical trial applications of Hengrui's three drugs were accepted, namely famitinib malate capsules, SHR-1802, and carrelizumab
Carrelizumab is a humanized anti-PD-1 monoclonal antibody that can bind to human PD-1 receptors and block the PD-1/PD-L1 pathway, restore the body’s anti-tumor immunity, thereby forming Fundamentals of Cancer Immunotherapy
Famitinib Malate Capsules is a small molecule multi-target tyrosine kinase inhibitor independently developed by Hengrui.
SHR-1802 is a monoclonal antibody targeting lymphocyte activation gene 3 protein (LAG3)